PEGASPARGASE

CRC (Colorectal Cancer)

Biotheus Inc.protein_peptidePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 81/ 100

Competitive context

18 Active assets in the CRC (Colorectal Cancer) cohort.

Asset / Sponsor	Phase	Rating
Daunorubicin Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.	Phase 3	BB
Shr-1701 Fudan University	Phase 2/3	B
Ruxolitinib Philogen S.p.A.	Phase 2	B
Inca33890 Incyte Corporation	Phase 3	B
pm8002 Biotheus Inc.	Phase 2	CCC

View all 19 →

Same molecule, other indications

PEGASPARGASE is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant

A

Indicative ·

80 / 100

Adult Acute Lymphocytic LeukemiaDormant

BBB

Indicative ·

77 / 100

extranodal nasal NK/T cell lymphomaDormant

BBB

Indicative ·

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.